Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-126 Gel Phase 2 Study in Acne Vulgaris
NCT03170388Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of clindamycin, adapalene and benzoyl peroxide + sulfur in acne vulgaris (5 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Inflammatory Lesion Counts at 12 weeks, Non-inflammatory Lesion Counts at 12 weeks and 1 more. Started Oct 2017; status: completed.
02
Drugs
clindamycinadapalenebenzoyl peroxide + sulfur
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03170388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170388.